Based on reported financial statement history.
Over longer horizons, Net Income CAGR averages 93.62% over 3 years and 32.73% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Net income CAGR shows how the company's bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
Ligand Pharmaceuticals Incorporated (LGND)
Net Income growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Reported quarterly net income; no daily interpolation. Q2 FY2026 (2026-06-30): $48.51M.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:47:10.696Z. Historical observations retain their original dates. Historical series through 2026-10-05.
| Year | Start Net Income | End Net Income | Change | % Change |
|---|---|---|---|---|
| 2025 | −$4.03M | $124.45M | +$128.49M | N/A |
| 2024 | $52.15M | −$4.03M | −$56.19M | -107.73% |
| 2023 | −$33.36M | $52.15M | +$85.52M | N/A |
| 2022 | $57.14M | −$33.36M | −$90.50M | -158.39% |
| 2021 | −$2.98M | $57.14M | +$60.12M | N/A |
| 2020 | $629.30M | −$2.98M | −$632.29M | -100.47% |
| 2019 | $143.32M | $629.30M | +$485.98M | +339.09% |
| 2018 | $12.56M | $143.32M | +$130.76M | +1041.45% |
| 2017 | −$1.64M | $12.56M | +$14.19M | N/A |
| 2016 | $257.31M | −$1.64M | −$258.94M | -100.64% |
| 2015 | $12.02M | $257.31M | +$245.28M | +2039.93% |
| 2014 | $11.42M | $12.02M | +$603.00K | +5.28% |
| 2013 | −$527.00K | $11.42M | +$11.95M | N/A |
| 2012 | $10.18M | −$527.00K | −$10.70M | -105.18% |
| 2011 | −$12.52M | $10.18M | +$22.69M | N/A |
| 2010 | −$1.95M | −$12.52M | −$10.57M | N/A |
| 2009 | −$98.11M | −$1.95M | +$96.17M | N/A |
| 2008 | $281.69M | −$98.11M | −$379.80M | -134.83% |
| 2007 | −$31.74M | $281.69M | +$313.43M | N/A |
| 2006 | −$36.40M | −$31.74M | +$4.66M | N/A |
| 2005 | −$45.14M | −$36.40M | +$8.74M | N/A |
| 2004 | −$37.46M | −$45.14M | −$7.68M | N/A |
| 2003 | −$32.60M | −$37.46M | −$4.87M | N/A |
| 2002 | −$42.99M | −$32.60M | +$10.40M | N/A |
| 2001 | −$72.38M | −$42.99M | +$29.38M | N/A |
| 2000 | −$74.70M | −$72.38M | +$2.32M | N/A |
| 1999 | −$117.90M | −$74.70M | +$43.20M | N/A |
| 1998 | −$100.20M | −$117.90M | −$17.70M | N/A |
| 1997 | −$37.30M | −$100.20M | −$62.90M | N/A |
| Period | Period End | Value | QoQ Growth | YoY Growth |
|---|---|---|---|---|
| Q2 FY2026 | 2026-06-30 | $48.51M | N/A | +900.8% |
| Q1 FY2026 | 2026-03-31 | -$13.35M | N/A | +68.6% |
| Q4 FY2025 | 2025-12-31 | $44.78M | -61.8% | N/A |
| Q3 FY2025 | 2025-09-30 | $117.27M | +2319.5% | N/A |
| Q2 FY2025 | 2025-06-30 | $4.85M | N/A | N/A |
| Q1 FY2025 | 2025-03-31 | -$42.45M | -36.6% |
Unrounded diluted TTM EPS / FMP quote price × 100 Quote observation: 2026-10-06T17:47:10.696Z. Historical observations retain their original dates. Historical series through 2026-10-05.
| N/A |
| Q4 FY2024 | 2024-12-31 | -$31.09M | -333.5% | N/A |
| Q3 FY2024 | 2024-09-30 | -$7.17M | +86.2% | +30.2% |
| Q2 FY2024 | 2024-06-30 | -$51.91M | N/A | N/A |
| Q1 FY2024 | 2024-03-31 | $86.14M | +373.6% | +105.3% |
| Q4 FY2023 | 2023-12-31 | $18.19M | N/A | N/A |
| Q3 FY2023 | 2023-09-30 | -$10.27M | N/A | N/A |
| Q2 FY2023 | 2023-06-30 | $2.29M | -94.5% | N/A |
| Q1 FY2023 | 2023-03-31 | $41.95M | N/A | N/A |
| Q4 FY2022 | 2022-12-31 | -$17.48M | N/A | -222.8% |
| Q3 FY2022 | 2022-09-30 | $404,000 | N/A | -97.1% |
QoQ Growth compares the previous fiscal quarter; YoY Growth compares the same fiscal quarter in the prior fiscal year. Missing or ambiguous fiscal periods render N/A.
